Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

octreotide acetate

OCTREOTIDE ACETATE

octreotide acetate (OCTREOTIDE ACETATE) is a somatostatin receptor agonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 13
Pipeline programs 8
News articles 0
Drug details — octreotide acetate
US status
approved
Class
—
Route
INJECTION
Patents
13
Programs
8
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

octreotide acetate (OCTREOTIDE ACETATE) is a somatostatin receptor agonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN octreotide acetate
Brand OCTREOTIDE ACETATE
Mechanism Somatostatin receptor agonist
Target Somatostatin receptor
Route INJECTION
Formulation INJECTABLE
Originator Teva Pharma GmbH

Mechanism of action

Somatostatin receptor agonist

Primary target: Somatostatin receptor

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. CAAA601A22301 Phase 3 · Advanced Accelerator Applications · Patients with somatostatin receptor positive, well-different
  2. CAAA601A62301 Phase 3 · Novartis India · Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
  3. HS-19-657 Phase 3 · Currus Biologics Pty · gastroenteropancreatic neuroendocrine tumors
  4. ALXN2420-Acro-201 Phase 2 · Alexion Europe SAS · Acromegaly
  5. OCTREOTIDE ACETATE, Paltusotine tablets Phase 2 · Anaxis Pharma · Carcinoid Syndrome
  6. Octreotide Acetate Phase 2 · United Therapeutics Europe · Liver Transplantation
  7. octreotide Phase 2 · Ultragenyx UK · Hereditary Hemorrhagic Telangiectasia
  8. Octreotide Phase 1 · Chinese Academy of · Enterocutaneous Fistulas

Related & competitor drugs

Browse all drugs
  1. paltusotine Systemic hormonal preparations (H01)
  2. lanreotide acetate Somatostatin receptor 5 agonist
  3. lutetium lu 177 dotatate Somatostatin receptor binding agent
  4. pasireotide diaspartate Somatostatin receptor 2 agonist
  5. pasireotide pamoate Somatostatin receptor 2 agonist
  6. lutetium (177lu) oxodotreotide Various (V10)

Related patents

Browse patents Teva Pharma GmbH patent hub

  1. EP 4541380

    STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN

    Expires Tue Apr 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. CA 3235923

    PROCEDES DE SYNTHESE A GRANDE ECHELLE DE COMPLEXES DE RADIONUCLEIDES

    Expires Wed Aug 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. CA 3240096

    POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON

    Expires Thu May 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. CA 3234495

    POLYTHERAPIE DE COMPLEXE DE RADIONUCLEIDES

    Expires Wed Apr 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. CA 3215723

    PROCEDES DE DIAGNOSTIC DU CANCER DE LA PROSTATE

    Expires Wed Oct 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2022043557

    MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA

    Expires Wed Feb 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2022043558

    MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA

    Expires Wed Feb 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. WO 2021219719

    PROCÉDÉS DE RADIOMARQUAGE DE LIGANDS SE LIANT AU PSMA ET LEURS KITS

    Expires Wed Oct 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2021219720

    PROCÉDÉS DE RADIOMARQUAGE DE LIGANDS DE LIAISON PSMA ET LEURS KITS

    Expires Wed Oct 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2021052960

    COMPOSITION RADIOPHARMACEUTIQUE CONCENTRÉE, STABLE

    Expires Wed Mar 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2020249818

    PROCÉDÉ DE TRAITEMENT DU CANCER PAR DÉPÔT INTRATUMORAL DE MICROPARTICULES RADIOACTIVES

    Expires Wed Dec 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 2020131224

    Methods for Synthesis of Radionuclide Complex

    Expires Wed Apr 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2020064693

    POLYTHÉRAPIE

    Expires Wed Mar 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is octreotide acetate?

octreotide acetate (OCTREOTIDE ACETATE) is a somatostatin receptor agonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for octreotide acetate?

OCTREOTIDE ACETATE is a marketed brand name for octreotide acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of octreotide acetate?

octreotide acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.